Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2014 /
Effective use of ibrutinib in the treatment of ABC lymphoma tumours

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 2196

Dr Louis Staudt - National Cancer Institute, Bethesda, USA

At a press conference during AACR, Dr Staudt discussed the results of a Phase II trial of a new drug, ibrutinib, in diffuse large B-cell lymphoma.

The first trial was promising, with a 40 percent response in ABC sub-type tumours which saw a survival rate which increased from 3 months on average to 10 months on average with few side effects.

However, the drug had no impact on GCB sub-type tumours, hence tests must be done to check which patients will be appropriate for such treatment, an area where genomics is especially important.

Staudt notes the great benefit of ibrutinib as there are significantly less side effects than chemotherapy and it has eradicated tumours, in some cases for years.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence